CureVac’s Defining Moment: Shareholders to Decide Company’s Fate

CureVac NL0015436031

The future of Tübingen-based biotech firm CureVac hangs in the balance as the company approaches a critical juncture. With operational performance weakening, shareholders face a landmark decision that will determine whether the company maintains its independence or becomes part of competitor BioNTech.

All eyes are fixed on tomorrow’s extraordinary general meeting scheduled for Tuesday, November 25, 2025. During this session, investors will cast their votes on resolutions necessary to advance the proposed transaction with BioNTech. Their approval represents the final hurdle before the public exchange offer can proceed, effectively deciding whether CureVac continues operating as an independent entity.

Strategic Rationale Behind mRNA Merger